Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preface.

Nicolle1, Wise, Wood

  • 1Vienna, Austria, March 2000.

The Journal of Antimicrobial Chemotherapy
|September 2, 2000
PubMed
Summary
This summary is machine-generated.

Urinary tract infections (UTIs) are common, with increasing antibiotic resistance posing treatment challenges. Pivmecillinam shows promise as an effective and safe option for managing UTIs due to its unique action and favorable profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Digitalis in Heart Diseases.

Atlanta medical and surgical journal·2022
Same author

Wood and Trees attend a conference.

Journal of the Intensive Care Society·2019
Same author

May the force be with you.

Journal of the Intensive Care Society·2018
Same author

Lemmingaid.

Journal of the Intensive Care Society·2018
Same author

Lost youth.

Journal of the Intensive Care Society·2017
Same author

General Paralysis of the Insane.

The Indian medical gazette·2017
Same journal

Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing.

The Journal of antimicrobial chemotherapy·2026
Same journal

A review of the randomized clinical trial results from the Staphylococcus aureus network adaptive platform (SNAP) meticillin-susceptible (MSSA) and penicillin-susceptible (PSSA) domains and CloCeBa.

The Journal of antimicrobial chemotherapy·2026
Same journal

Incidence and factors associated with subtherapeutic cefazolin levels among patients with severe infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Emerging resistance in staphylococci following long-term dalbavancin treatment for prosthetic joint infections.

The Journal of antimicrobial chemotherapy·2026
Same journal

Microbiology testing around the time of antibiotic initiation among residents of long-term care facilities.

The Journal of antimicrobial chemotherapy·2026
Same journal

Insights into the mechanisms underlying cell wall-active agents and gentamicin bactericidal synergism against Enterococcus faecalis.

The Journal of antimicrobial chemotherapy·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Urology

Background:

  • Lower urinary tract infections (UTIs) are a common condition, accounting for a significant percentage of general practitioner consultations and antibiotic prescriptions.
  • Uropathogenic bacteria are developing resistance to widely used antibiotics like trimethoprim and ampicillin, with resistance rates often exceeding 30-50%.
  • The emergence of antibiotic resistance necessitates a reevaluation of current UTI treatment strategies and the exploration of alternative antimicrobial agents.

Purpose of the Study:

  • To review current perspectives on the diagnosis and treatment of UTIs in light of evolving microbial resistance patterns.
  • To evaluate the potential role of pivmecillinam in the management of UTIs, considering its pharmacological properties and clinical efficacy.

Main Methods:

Related Experiment Videos

  • This supplement synthesizes information presented at a March 2000 meeting in Vienna, Austria, sponsored by Leo Pharmaceutical Laboratories.
  • It draws upon existing clinical experience and scientific data regarding UTI treatment and antimicrobial resistance.

Main Results:

  • Antibiotic resistance to common UTI treatments is a growing concern, complicating clinical decision-making.
  • Pivmecillinam, hydrolyzed to mecillinam, exhibits a novel mechanism of action, rapid bacterial penetration, and reduced susceptibility to beta-lactamases.
  • Clinical experience across multiple countries suggests pivmecillinam is a suitable candidate for UTI treatment due to its spectrum of activity and safety profile.

Conclusions:

  • The increasing prevalence of antibiotic resistance in uropathogens requires a reconsideration of treatment options for UTIs.
  • Pivmecillinam's unique properties and established efficacy suggest it could play a significant role in the contemporary management of UTIs.